Brief: Jasper Therapeutics Announces First Patient Dosed In A Phase 1 Trial Of Briquilimab In Lower-Risk Myelodysplastic Syndrome
22/06/2023 13:16
June 22 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN A
PHASE 1
TRIAL OF BRIQUILIMAB IN LOWER-RISK MYELODYSPLASTIC SYNDROME
Source text for Eikon: ID:nGNX2YVpwg
Further company coverage: JSPR.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma